Skip to main content
OpenTrials
Completed

NCT Number: NCT00325299

Magnesium After Alcohol Withdrawal Treatment

The primary purpose is to see if magnesium tablet supplementation will decrease elevated GGT enzyme activity in alcoholic patients immediately after they had been treated for alcohol withdrawal. The secondary aims are to find out whether supplementation decreases the activity of ASAT and ALAT enzymes, increases muscle strength, decreases blood pressure and decreases depressive symptoms among these patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–64 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Finnish Foundation for Alcohol Studies

Helsinki, 00531, Finland

About this study

Magnesium (Mg) deficiency is common among alcoholics. Animal studies have shown that magnesium deficiency aggravates the hepatic damage caused by alcohol. One study on chronic alcoholics suggested that magnesium supplementation over six weeks decreases abnormally high activities of three enzymes related to liver function: serum gamma-glutamyltransferase (GGT), aspartate-aminotransferase (ASAT) and alanine-aminotransferase (ALAT), and increases muscle strength [4]. These results were, however, significant at the 5% level only when a 1-sided test was applied. It seems that magnesium supplementation may improve liver recovery after a drinking bout, but the evidence is not yet strong enough to warrant clear recommendations for clinical practice. Magnesium deficiency may also be one of the symptoms of depression and may aggravate hypertension. The primary purpose of the present randomized, parallel group, double blind trial is to see if oral magnesium supplementation will decrease elevated GGT enzyme activity in alcoholic patients immediately after they had been treated for alcohol withdrawal. The secondary aims are to find out whether supplementation decreases the activity of ASAT and ALAT enzymes, increases muscle strength, decreases blood pressure and decreases depressive symptoms among these patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Admission to treatment because of an acute alcohol withdrawal
  • Elevated serum GGT (men>80, women >50)
  • Age 20-64 years
  • Fixed address and a telephone to facilitate follow-up

Exclusion criteria

  • Mg supplementation within the past two months ten 250 mg tablets or more
  • History of heart rhythm disturbances
  • Contraindications against Mg treatment
  • Abnormally high serum creatinine

Treatment and study plan

Magnesium

Drug

Primary outcomes

  1. Serum gamma-glutamyltransferase (GGT) activity

Secondary outcomes

  1. Aspartate-aminotransferase (ASAT) activity

  2. Alanine-aminotransferase (ALAT) activity

  3. Depressive symptoms

  4. Blood pressure

  5. Handgrip muscle strength

Sponsors and collaborators

Lead sponsor

Finnish Foundation for Alcohol Studies

Other

Registry information

Important dates

Study completion
2005
First posted
May 12, 2006
Registry last updated
May 12, 2006

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.